NCT02451098View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

PHASE3CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions
Hyperlipidemia
Interventions
DRUG

Atorvastatin10mg, Ezetimibe10mg

Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin10mg, Ezetimibe placebo

Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)

DRUG

Atorvastatin20mg, Ezetimibe10mg

Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin20mg, Ezetimibe placebo

Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)

DRUG

Atorvastatin40mg, Ezetimibe10mg

Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin40mg, Ezetimibe placebo

Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)

Trial Locations (1)

Unknown

The catholic university of korea seoul st. Mary's hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY